PRIMARY TUMOUR DIAMETER AS A RISK FACTOR FOR METASTASES IN DIFFERENTIATED THYROID CARCINOMA

Luster M., Verburg F., Mäder U., Reiners Ch. University Clinic W?rzburg, W?rzburg, Germany Abstract Objectives: In differentiated thyroid carcinoma a larger tumour diameter is considered to indicate a poorer prognosis. This higher risk is most likely effectuated due to a higher rate of metastases and locally invasive growth in patients with larger carcinomas. The aim Read More

PAPILLARY THYROID CANCERS

Perrino M.1, Vannucchi G.1, Colombo C.1, Vicentini L.2, Chiti A.3, Beck Peccoz P.1, Fugazzola L.1 1Department of Medical Sciences, Endocrine Unit Unviversity of Milan, IRCCS Fondazione Policlinico, Milan, Italy, 2Endocrine Surgery Unit, IRCCS Fondazione Policlinico, Milan, Italy, 3Nuclear Medicine Unit, IRCCS Istituto Clinico Humanitas, Milan, Italy Abstract The incidence of papillary thyroid cancer (PTC) is Read More

THE EFFECT OF PROLONGED ROSIGLITAZONE THERAPY IN PATIENTS WITH METASTATIC RADIOIODINE-NEGATIVE DIFFERENTIATED THYROID CARCINOMA

K?hne-Eversmann L.1, Weiss M.2, Pfluger T.2, Gaertner R.1 1Department of Endocrinology, Medizinische Klinik Innenstadt, University of Munich, 2Department of Nuclear Medicine, Innenstadt, University of Munich Abstract Objective: Patients with metastases of differentiated thyroid carcinoma that fail to trap iodine or are unresectable have a poor prognosis. Recent studies with PPAR-γ agonists have shown promising effects Read More

HSP90 INHIBITION AS A NOVEL THERAPEUTIC APPROACH FOR THE TREATMENT OF AGGRESSIVE THYROID CARCINOMAS

McMillin W.D.1, Kotoula V.2, Negri J.1, Hayden P.1, Koletsa T.2, Mitsiades S.C.1, Mitsiades N.1, 3 1Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston MA, USA, 2Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Memorial Sloan Kettering Cancer Center, New York, USA Abstract Context: Read More

PNEUMOTHORAX DUE TO MASSIVE TUMOR LYSIS IN A PATIENT WITH SORAFENIB THERAPY FOR METASTASIZED DIFFERENTIATED THYROID CARCINOMA

Hoftijzer H.1, Heemstra K.1, Blaauwwiekel E.2, Corssmit E.1, Romijn J.1, Smit J.1 1Department of Endocrinology and metabolism, Leiden University medical Center, Leiden, The Netherlands, 2Department of Internal Medicine, Nij Smellinghe Hospital, Drachten, The Netherlands Abstract Background: Treatment options for metastases of differentiated thyroid carcinoma with absent uptake of radioiodine (RaI) are limited. Broad spectrum tyrosine Read More

ANTI-TUMOR EFFECTS OF THE TYROSINE KINASE INHIBITORS SUNITINIB (SU11248) AND VANDETANIB (ZD6474) IN HUMAN THYROID CARCINOMA CELL LINES

Charalambous E.1,2, Kotoula V.1, Hayden P.2, McMillin W.D.2, Negri J.2, Mitsiades S.C.2, Mitsiades N.2, 3 1Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, 2Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston MA, USA., 3Memorial Sloan Kettering Cancer Center, New York, USA Abstract Context: Read More

ROLE OF BASAL AND PENTAGASTRIN STIMULATED CALCITONIN IN TAKING THE DECISION TO PERFORM THYROIDECTOMY IN GENE CARRIERS OF RET MUTATIONS

Romei C., Botici V., Cosci B., Renzini G., Molinaro E., Agate L., Pinchera A., Elisei R. Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy Abstract Multiple Endocrine Neoplasia type 2 (MEN 2) is characterized by the presence of medullary thyroid cancer (MTC) and other benign pathologies. RET mutations are responsible of this disease Read More

VANDETANIB (100 MG) IN METASTATIC HEREDITARY MEDULLARY THYROID CANCER: A PHASE II OPEN-LABEL STUDY

Robinson B.1, Paz-Ares L.2, Krebs A.3, Vasselli J.3, Haddad R.4 1Kolling Institute of Medical Research, University of Sydney, Australia, 2Doce de Octubre University Hospital, Madrid, Spain, 3AstraZeneca, Wilmington, DE, USA, 4Dana-Farber Cancer Institute, Boston, MA, USA Abstract Objectives: Vandetanib (ZACTIMA™) is a once-daily oral agent that selectively targets RET, VEGFR and EGFR signalling pathways. Vandetanib Read More

EXPRESSION AND SUBCELLULAR LOCALIZATION OF JAB1 AND P27

Lee S., Ahn J., Chung Y.J. Internal medicine, Chung-Ang University Hospital, Seoul, Korea Abstract Down-regulation of p27Kip1, which is well-known cell cycle inhibitor, is associated with advanced stage of cancer and poor patient survival. However, recent studies show that cytoplasmic localization of p27Kip1 would be more meaningful rather than expression levels in terms of cancer Read More

FATE MAPPING REVEAL THAT MIDLINE THYROID PROGENITORS ARISE FROM SONIC HEDGEHOG (SHH) NEGATIVE FOREGUT ENDODERM BUT SHH POSITIVE CELLS ENTER THE THYROID VIA THE PHARYNGEAL POUCHES

Nilsson M., Westerlund J., Fagman H. Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden Abstract The thyroid develops from distinct regions in the foregut endoderm, the midline and lateral primordia. To date no cell-autonomous factor responsible for the early specification of thyroid progenitor cells has been uncovered. Read More